1stOncology™: Cancer Intelligence Service – Page 12617 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Novocure Reports Second Quarter 2020 Financial Results and Provides Company Update

On July 30, 2020 Novocure (NASDAQ: NVCR) reported financial results for the quarter ended June 30, 2020, highlighting revenue growth and financial strength as well as the advancement of the company’s clinical and product development programs (Press release, NovoCure, JUL 30, 2020, View Source [SID1234562604]). Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

An "active patient" is a patient who is receiving treatment under a commercial prescription order as of the measurement date, including patients who may be on a temporary break from treatment and who plan to resume treatment in less than 60 days.

A "prescription received" is a commercial order for Optune or Optune Lua that is received from a physician certified to treat patients for a patient not previously on Optune or Optune Lua. Orders to renew or extend treatment are not included in this total.

"Our track record of execution extended into the second quarter 2020 with sustained commercial momentum driving strong financial performance that allowed us to fund increased investments supporting the advancement of Tumor Treating Fields’ science and technology," said William Doyle, Novocure’s Executive Chairman. "There were several notable achievements since our last earnings call, including last patient enrollment in the HEPANOVA trial, announcement of a clinical collaboration with MSD (a tradename of Merck & Co., Inc., through a subsidiary) in first-line non-small cell lung cancer, and launch of the EF-33 trial to study Tumor Treating Fields delivered with a high-intensity array in recurrent GBM, and we remain determined to advance our strategic priorities to unlock the long-term potential of our proprietary platform."

"We further strengthened our foundation for growth in Q2," added Asaf Danziger, Novocure’s Chief Executive Officer. "Our GBM business delivered a record $116 million in global net revenues, we reported positive EPS of $0.02, and Optune received regulatory approval for the treatment of GBM in China. With nearly 3,300 active patients on therapy at the end of the quarter, we added to the more than 16,000 patients treated to-date, globally. We remain confident in our team, our strategy and in the potential of our therapy to extend survival in some of the most aggressive forms of cancer."

Second quarter 2020 operating statistics and financial update

For the quarter ended June 30, 2020, net revenues were $115.9 million, representing 34% growth compared to the second quarter 2019.

In the United States, net revenues totaled $81.2 million in the quarter ended June 30, 2020, representing 38% growth compared to the same period in 2019.
In Germany and other EMEA markets, net revenues totaled $25.4 million in the quarter ended June 30, 2020, representing 13% growth compared to the same period in 2019.
In Japan, net revenues totaled $7.2 million in the quarter ended June 30, 2020, representing 72% growth compared to the same period in 2019.
In Greater China, net revenues totaled $2.1 million in the quarter ended June 30, 2020, representing 97% growth compared to the same period in 2019.
There were 3,278 active patients at June 30, 2020, representing 20% growth compared to June 30, 2019, and six percent growth compared to March 31, 2020.

In the United States, there were 2,143 active patients at June 30, 2020, representing 16% growth compared to June 30, 2019.
In Germany and other EMEA markets, there were 900 active patients at June 30, 2020, representing 22% growth compared to June 30, 2019.
In Japan, there were 235 active patients at June 30, 2020, representing 64% growth compared to June 30, 2019.
Additionally, 1,422 prescriptions were received in the quarter ended June 30, 2020, representing four percent growth compared to the same period in 2019, and one percent growth compared to the quarter ended March 31, 2020. In the quarter ended June 30, 2020, 1,156 Optune prescriptions were written for patients with newly diagnosed glioblastoma.

In the United States, 968 prescriptions were received in the quarter ended June 30, 2020, representing a two percent decrease compared to the same period in 2019.
In Germany and other EMEA markets, 369 prescriptions were received in the quarter ended June 30, 2020, representing 23% growth compared to the same period in 2019.
In Japan, 85 prescriptions were received in the quarter ended June 30, 2020, representing 15% growth compared to the same period in 2019.
For the three months ended June 30, 2020, cost of revenues was $25.5 million compared to $21.1 million for the same period in 2019, representing an increase of 21%. The increase was primarily due to the cost of shipping transducer arrays to a higher volume of commercial patients, partially offset by benefits of ongoing efficiency initiatives and scale. Gross margin was 78% for the three months ended June 30, 2020 and 76% for the three months ended June 30, 2019.

Research, development and clinical trials expenses for the three months ended June 30, 2020, were $29.9 million compared to $19.5 million for the same period in 2019, representing an increase of 54%. This was primarily due to an increase in clinical trial and personnel expenses for our phase 3 pivotal and phase 4 post-marketing trials, an increase in development and personnel expenses to support our product development programs, increased investments in preclinical research and the expansion of our medical affairs activities.

Sales and marketing expenses for the three months ended June 30, 2020, were $28.5 million compared to $23.7 million for the same period in 2019, representing an increase of 20%. This was primarily due to an increase in personnel costs to support our growing commercial business and reimbursement efforts and an increase in marketing expenses related to the launch of Optune Lua for malignant pleural mesothelioma.

General and administrative expenses for the three months ended June 30, 2020 were $25.4 million compared to $21.2 million for the same period in 2019, representing an increase of 20%. This was primarily due to an increase in personnel costs, insurance premiums and professional services.

Net income for the three months ended June 30, 2020 was $1.7 million compared to a net loss of $1.3 million for the same period in 2019.

At June 30, 2020, we had $196.8 million in cash and cash equivalents and $149.9 million in short-term investments, for a total balance of $346.7 million in cash, cash equivalents and short-term investments. This represents an increase of $15.4 million in cash and investments since March 31, 2020.

Second quarter 2020 non-U.S. GAAP measures

We also measure our performance based upon a non-U.S. GAAP measurement of earnings before interest, taxes, depreciation, amortization and shared-based compensation ("Adjusted EBITDA"). We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare the results of our operations from period to period by removing the impact of earnings attributable to our capital structure, tax rate and material non-cash items, specifically share-based compensation.

Adjusted EBITDA was $28.0 million for the three months ended June 30, 2020, an increase of $10.9 million, or 64%, from $17.1 million for the three months ended June 30, 2019. This improvement in fundamental financial performance was driven by net revenue growth coupled with an ongoing commitment to disciplined management of expenses.

Anticipated clinical milestones

Data from phase 2 pilot HEPANOVA trial in advanced liver cancer (2021)
Data from phase 2 pilot EF-31 trial in gastric cancer (2021)
Interim analysis of phase 3 pivotal LUNAR trial in non-small cell lung cancer (2021)
Interim analysis of phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2021)
Interim analysis of phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (2021)
Data from phase 3 pivotal METIS trial in brain metastases (2022)
Data from phase 2 pilot EF-33 trial with high-intensity arrays in recurrent glioblastoma (2022)
Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2023)
Final data from phase 3 pivotal PANOVA-3 trial in locally advanced pancreatic cancer (2023)
Final data from phase 3 pivotal INNOVATE-3 trial in recurrent ovarian cancer (2023)
Conference call details

Novocure will host a conference call and webcast to discuss second quarter 2020 financial results at 8 a.m. EDT today, Thursday, July 30, 2020. Analysts and investors can participate in the conference call by dialing 855-442-6895 for domestic callers and 509-960-9037 for international callers, using the conference ID 1484689.

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37

On July 30, 2020 Nordic Nanovector ASA (OSE: NANO) is reported the grant of an EU patent covering the use of Alpha37 for the treatment of Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) (Press release, Nordic Nanovector, JUL 30, 2020, View Source [SID1234562603]). Alpha37 is an investigational radioimmunoconjugate developed by Nordic Nanovector in collaboration with Orano Med comprising a proprietary chimeric CD37-targeting antibody conjugated to the alpha-particle generating radionuclide lead-212.

Alpha37 has completed preclinical development, during which it demonstrated promising immunogenicity, biodistribution and targeted tumour-cell killing results in preclinical lymphoma and leukaemia models. Preclinical data presented at international cancer congresses during the past year have shown that a single injection of Alpha37 is well-tolerated and produces a promising anti-cancer effect and subsequent improvement on survival in preclinical models of CD37-positive CLL and NHL.

Jostein Dahle, CSO of Nordic Nanovector, said: "We are pleased to receive this patent protection for Alpha37 in the European Union. We view Alpha37 as a complementary candidate to Betalutin based on its differentiated therapeutic profile and potential to treat CLL and NHL. Our preclinical Alpha37 programme represent a pipeline asset that leverages our strong expertise in radioimmunoconjugates."

EU patent no. 3272364, which is entitled "Chimeric Therapeutic Antibodies" will be active until 2032 with the option of prolonging for five 5 additional years.

Enterome initiates first clinical trial with EO2401 – an innovative microbiome-antigen (‘OncoMimic’) based cancer immunotherapy candidate targeting aggressive brain cancer

On July 30, 2020 ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, reported it has initiated its first clinical trial with EO2401, an innovative microbiome-antigen (‘OncoMimic’) based cancer immunotherapy candidate (Press release, Enterome, JUL 30, 2020, View Source;an-innovative-microbiome-antigen-oncomimic-based-cancer-immunotherapy-candidate-targeting-aggressive-brain-cancer-301102573.html [SID1234562602]). The Phase 1/2 (‘ROSALIE’) clinical trial is investigating EO2401 in combination with an immune checkpoint inhibitor as a potential new treatment for progressive or first recurrent glioblastoma multiforme (GBM), an aggressive form of brain cancer for which no cure exists. Initial clinical data from the ROSALIE study are expected in 2022.

EO2401 is an innovative, off-the-shelf immune-oncology candidate derived from Enterome’s revolutionary ‘OncoMimic’ platform. OncoMimics are microbiome-derived peptide antigens that closely mimic antigens expressed by tumor cells; they are selected based on their ability to trigger the rapid activation of memory T-cells that respond to gut bacteria and to direct a targeted cell-killing immune response against the tumor. EO2401 combines three OncoMimics present in aggressive cancers such as glioblastoma.

The first clinical trial with EO2401 (ROSALIE, NCT04116658) is a multicenter, open-label, Phase 1/2 study assessing its safety, tolerability, immunogenicity and preliminary efficacy in combination with a checkpoint inhibitor in patients with GBM. A total of 32 patients are expected to be enrolled at 10 clinical sites in Europe and the US.

Prof. Wolfgang Wick, MD, Chairman, Department of Neurology, Heidelberg University Hospital (Heidelberg, Germany), is ROSALIE’s Principal Investigator. Professor Wick is a globally renowned neuro-oncologist with extensive clinical research experience in the field of primary and recurrent brain tumors.

Prof. Wolfgang Wick, MD, said: "There is an urgent need to find a truly effective treatment for glioblastoma to help prevent recurrent or further progression of this deadly form of brain tumor. We have seen increasing evidence of the influence of the gut microbiome over immune responses to cancer and cancer immunotherapies. EO2401 is based on a novel concept that builds on this understanding and I am excited to participate in this first clinical trial with EO2401."

Jan Fagerberg, CMO of Enterome, said: "This first-in-human trial evaluating EO2401 in patients with glioblastoma is a significant milestone for Enterome. EO2401 is the first targeted immunotherapy generated from our unique OncoMimics immunotherapy platform. This novel approach capitalizes on the finding that certain bacterial antigens derived from the gut microbiota bear striking molecular similarities to antigens found in human tumors. We are confident that these similarities will enable our so-called ‘OncoMimics’ to trigger powerful and targeted immune responses against specific cancers, including glioblastoma. We believe that this concept can be applied against multiple cancers. We are proud and pleased to be able to begin clinical studies with EO2401 and to position Enterome as a leader of next-generation cancer immunotherapies."

Enterome will start a second clinical study in patients with adrenal malignancies in the coming weeks and plans to initiate another clinical study in patients with B-cell malignancies in 2021.

Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress

On July 30, 2020 Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, reported its financial results for the second quarter ended June 30, 2020, and provided an update on its R&D pipeline and other corporate developments (Press release, Lantern Pharma, JUL 30, 2020, View Source [SID1234562601]).

"Lantern Pharma achieved important scientific and operational milestones during the quarter that have us well positioned for growth as we focus on being the leader in A.I.-enabled oncology drug development," said Panna Sharma, CEO and President of Lantern Pharma. "Our proprietary RADR platform recently surpassed 500 million data points, further accelerating our path to one billion curated oncology data points in the next few quarters. We have also advanced our manufacturing capabilities and network for our upcoming clinical trials for LP-300 in non-small cell lung cancer among never smokers, and for LP-184 in genomically defined solid tumors and glioblastoma. On June 15, we completed a successful IPO, raising gross proceeds of $26.3 million, significantly strengthening the Company’s balance sheet and provides additional resources to support the continued development of our promising and growing pipeline of targeted cancer therapies. Our approach and vision is to bring cancer therapies to market faster and with reduced cost and risk and ultimately improve patient outcomes. We are entering what I believe is the Golden Age of A.I. where industries will continue to be rapidly transformed and massive advancements made that can benefit medicine, health and those willing to invest in and develop these disruptive opportunities."

Corporate and Scientific Highlights

Closed initial public offering – In June 2020, Lantern Pharma closed its initial public offering of 1,750,000 shares of its common stock at a public offering price of $15.00 per share, for gross proceeds of $26,250,000, before deducting underwriting discounts, commissions and offering expenses.
Initiated multiple preclinical studies for LP-184 in genomically defined solid tumors and Glioblastoma (GBM) – The studies aim to further validate the genomic signature of LP-184 and help to inform IND development efforts. The data generated in these studies will also support the continued expansion of our RADR (Response Algorithm for Drug Positioning and Rescue) A.I. platform.
RADR surpasses 500 million data points – Lantern Pharma is ahead of its initial platform development schedule of reaching 400 million data points by the end of 2020. The Company is now on track to reach over 1 billion data points within the next several quarters.
Presented at American Association for Cancer Research (AACR) (Free AACR Whitepaper) – Two presentations that detailed Lantern Pharma’s use of its RADR A.I. platform in the development of LP-184, a molecule with nanomolar potency and strong activity in cancers with KEAP1 and KRAS mutations. LP-184 is one of three cancer drug candidates in Lantern Pharma’s pipeline.
Advanced manufacturing capabilities and network to support LP-300 and LP-184 trials – the Company established a manufacturing network in preparation for its Phase 2 clinical trial of LP-300 in non-small cell lung cancer among never smokers and for LP-184 in preclinical development for genomically defined solid tumors that overexpress certain RNA as well as for glioblastoma multiforme.
Continue to advance our collaborations with leading academic and cancer research centers – for the purposes of examining additional potential cancer indications for our drugs, improving and validating the existing genomic signatures that correspond to patient response, establishing sites, and recruiting potential investigators for upcoming clinical trials.
Q2 2020 Financial Highlights

Cash Position: Cash and cash equivalents were $23.8 million as of June 30, 2020, compared to $1.2 million as of December 31, 2019. The increase was primarily due to proceeds from the IPO in June 2020.

R&D Expenses: Research and development expenses were $157,023 for the quarter ended June 30, 2020, compared to $361,273 for the quarter ended June 30, 2019. The decrease was primarily attributable to reductions in product candidate manufacturing related expenses reflecting completion of process development and scale-up studies conducted in the prior year period.

G&A Expenses: General and administrative expenses were $676,399 for the quarter ended June 30, 2020, compared to $268,120 for the quarter ended June 30, 2019. This increase was primarily due to an increase in expenses associated with transitioning to and becoming a public company.

Net Loss: Net loss was $833,422 for the quarter ended June 30, 2020, compared to a net loss of $629,393 for the quarter ended June 30, 2019.

Sharma continued, "Developing drugs by leveraging artificial intelligence is central to transforming the cost and efficiency of the pharma industry and improving the personalization of therapies for cancer patients. By identifying clinical candidates, together with relevant genomic, clinical and phenotypic data, we believe our approach will help us design more efficient pre-clinical studies and more targeted clinical trials, thereby accelerating our drug candidates’ time to approval and eventually to market. RADR is central to our process in achieving this outcome rapidly and with reduced costs. We currently have three compounds in development, one in a Phase 2 trial in prostate cancer with our partner, Oncology Venture, one that is preparing to enter into a Phase 2 trial, and one in preclinical development."

"We believe we have developed a sustainable and scalable biopharma business model by combining a unique, oncology-focused big-data platform that leverages artificial intelligence and machine learning with active clinical and preclinical programs that are being advanced in targeted cancer therapeutic areas with significant clinical needs," concluded Sharma.

Conference Call:

Lantern Pharma will host a conference call and webcast today at 8:00 a.m. ET.

Conference Call & Webcast Details

Toll-free Domestic & Canada: 800.791.4813 – conference ID 10552
International: 785-424-1102 – conference ID 10552
US and Canada callers one touch dial: +1.800.791.4813,,10552#
The webcast will be available in the "Investors" section of the company website at View Source under the News & Events page.

Replay Details

A replay of the conference call will be available for replay until 11:59 pm ET August 30, 2020.
Replay Number: 1-888-567-0053, no passcode will be needed.

A live audio-only webcast and related presentation materials will also be accessible on the Lantern Pharma corporate website: View Source. Web participants are encouraged to register 15 minutes prior to the start of the call. The webcast will be archived on the Lantern Pharma website for 6 months.

Gan & Lee Pharmaceuticals Initiates First-in Human Phase 1 Clinical Trial for New Anti-tumor Drug GLR2007

On July 30, 2020 Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), reported that with the initiation of our first-in-human Phase 1 clinical trial for GLR2007, our internally-invented, cyclin-dependent kinase 4/6 (CDK4/6) inhibitor as a potential therapy for advanced solid tumors (Press release, Gan and Lee Pharmaceuticals, JUL 30, 2020, View Source;lee-pharmaceuticals-initiates-first-in-human-phase-1-clinical-trial-for-new-anti-tumor-drug-glr2007-301103340.html [SID1234562599]). CDK4/6 activity is central to cell cycle regulation and has a key role in the occurrence and progression of a variety of cancers.1 2 Therefore, Gan & Lee views CDK4/6 as an attractive therapeutic target agent. This Phase 1 clinical trial is a multicenter, open- label, study designed to establish the safety, tolerability, and optimal dosing strategy of GLR2007 in patients with advanced solid tumors. Dr. Lawrence Hill, CEO, Gan & Lee US says, "Based on encouraging pre-clinical data and the high unmet need, 3 GLR2007 is a promising new investigational compound that could potentially address unmet medical need for patients with advanced solid tumors. We are excited to begin this Phase 1 clinical study (NCT04444427) and look forward to collaborating with patients, caregivers and the medical community to make a meaningful difference to people living with cancer."